As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of enVVeno Medical Corp. The largest reported stake is Thomas A. Satterfield, Jr.'s, at 9%. 12 filings are on record since September 9, 2025 (Schedule 13G, November 19, 2025).
Sell to companies like enVVeno Medical Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Braeden Lichti · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-15
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 24,605 · Sole dispositive: 0 · Shared dispositive: 24,605 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Kingdon Capital Management, L.L.C. · Percent: 5.5% · SCHEDULE 13G/A
- · Holder: Perceptive Advisors LLC · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: Northstrive Fund II LP · Percent: 5.05% · Shares: 20,129 · SCHEDULE 13D
enVVeno Medical Corp has 12 Schedule 13D or 13G filings on record since 2025-09-09. 3 holders' latest filing reports 5% or more of common stock, par value $0.00001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Thomas A. Satterfield, Jr. | 9% | 1,822,500 | SCHEDULE 13G, 2025-11-19 | 2025-11-14 |
| Kingdon Capital Management, L.L.C. | 5.5% | 36,166 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Northstrive Fund II LP | 5.05% | 20,129 | SCHEDULE 13D, 2026-02-20 | 2026-02-20 |
| Perceptive Advisors LLC | 3.5% | 24,605 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Nantahala Capital Management, LLC | 3.46% | 688,940 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| 0% | 0 | SCHEDULE 13D/A, 2026-09-15 | 2026-09-11 |
Holding shares or following this stake? See who's behind enVVeno Medical Corp and the warning signs.
Free to see. No signup.
Keep reading
More on enVVeno Medical Corp and the records around it.
enVVeno Medical Corp elsewhere on the record
Companies that share a holder
- Kingdon Capital Management, L.L.C. also filed stake reports on 2 other companies: SCYNEXIS INC (Feb 2026), Jasper Therapeutics, Inc. (Nov 2025)
- Northstrive Fund II LP also filed stake reports on 2 other companies: Bluejay Diagnostics, Inc. (Jun 2026), ENVERIC BIOSCIENCES, INC. (Dec 2025)
- Braeden Lichti also filed stake reports on 3 other companies: PMGC Holdings Inc. (Jun 2026), Bluejay Diagnostics, Inc. (Jun 2026), ENVERIC BIOSCIENCES, INC. (Dec 2025)
Watch enVVeno Medical Corp
Get an email when enVVeno Medical Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on enVVeno Medical Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on enVVeno Medical Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on enVVeno Medical Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 0 | 24,605 | 0 | 24,605 | SCHEDULE 13G/A, 2026-08-14 |
| Joseph Edelman | 0 | 24,605 | 0 | 24,605 | SCHEDULE 13G/A, 2026-08-14 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 24,605 | 0 | 24,605 | SCHEDULE 13G/A, 2026-08-14 |
| Braeden Lichti | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-09-15 |
| Northstrive Fund II LP | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-09-15 |
The latest filing identifies enVVeno Medical Corp by CUSIP 29415J205 and gives its principal executive office as 70 Doppler, Irvine, CA 92618 (SCHEDULE 13D/A, 2026-09-15).
Source of funds (Item 3)
The information set forth in Item 4 is incorporated by reference herein. Mr. Lichti previously used personal funds to purchase his previously owned Common Stock. Northstrive Fund previously used working capital as the source of funds for the purchase of its previously owned Common Stock.Braeden Lichti, SCHEDULE 13D/A, 2026-09-15
Purpose of Transaction (Item 4)
Braeden Lichti
On September 11, 2026, Braeden Lichti sold all of his previously owned shares of the Issuer's Common Stock and no longer owns any shares of Common Stock. From September 11, 2026 to September 14, 2026, NorthStrive Fund II LP sold all of its previously owned shares of the Common Stock, and no longer owns any shares of Common Stock. Previously, the Reporting Persons herein filed a Schedule 13D with the U.S. Securities and Exchange Commission on February 20, 2026 ("Schedule 13D"), which reported the number of shares held by each reporting person as of February 20, 2026. This Schedule 13D/A filing is the final amendment to the Schedule 13D and constitutes an exit filing for Braeden Lichti and NorthStrive Fund II LP.Item 4 of the SCHEDULE 13D/A filed 2026-09-15
Northstrive Fund II LP
As of February 10, 2026, the Reporting Persons beneficially owned 33,151 shares of Common Stock, representing 5.05% of the Issuer's issued and outstanding Common Stock. This percentage was calculated based on 655,606 shares of the Issuer's issued and outstanding shares of Common Stock on January 20, 2026, as reported on the Issuer's Current Report on Form 8-K filed with the Commission on January 20, 2026. On February 10, 2026, neither of the Reporting Persons had control or influence intent in the Issuer. This Schedule 13D is being filed to disclose Northstrive's Fund letter to the Board of Directors of the Issuer dated February 20, 2026 (the "Board Letter"). The Board Letter includes, among other things, Northstrive's Fund recommendations to the Board to immediately halt all clinical operations and launch a formal strategic review to either return capital to shareholders or pursue a merger or reverse merger to maximize shareholder value while preserving cash and minimizing further burn and dilution. Northstrive Fund has requested to meet with the senior management of the Issuer in the Board Letter. The Board Letter is filed herein as Exhibit A. As the Board Letter indicates an intent by the Reporting Persons with a purpose or effect to potentially change or influence control of the Issuer, the Reporting Persons have deemed it appropriate to amend the Schedule 13G by filing this Schedule 13D. The Reporting Persons intend to review their investment in the Issuer on a …The first part of Item 4 of the SCHEDULE 13D filed 2026-02-20; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-09 | Kingdon Capital Management, L.L.C. | 7.1% | SCHEDULE 13G |
| 2025-11-14 | Nantahala Capital Management, LLC | 3.46% | SCHEDULE 13G/A |
| 2025-11-19 | Thomas A. Satterfield, Jr. | 9% | SCHEDULE 13G |
| 2026-02-10 | Braeden Lichti | 5.05% | SCHEDULE 13G |
| 2026-02-10 | Braeden Lichti | 5.05% | SCHEDULE 13G |
| 2026-02-17 | Perceptive Advisors LLC | 9.99% | SCHEDULE 13G/A |
| 2026-02-20 | Northstrive Fund II LP | 5.05% | SCHEDULE 13D |
| 2026-02-20 | Braeden Lichti | 5.05% | SCHEDULE 13D |
| 2026-05-15 | Kingdon Capital Management, L.L.C. | 5.5% | SCHEDULE 13G/A |
| 2026-05-15 | Perceptive Advisors LLC | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | Perceptive Advisors LLC | 3.5% | SCHEDULE 13G/A |
| 2026-09-15 | Braeden Lichti | 0% | SCHEDULE 13D/A |
Questions about who owns enVVeno Medical Corp
Who owns enVVeno Medical Corp?
On this page, 3 holders' latest ownership filings report 5% or more of enVVeno Medical Corp: Thomas A. Satterfield, Jr. (9%, Schedule 13G, filed 2025-11-19), Kingdon Capital Management, L.L.C. (5.5%, Schedule 13G/A, filed 2026-05-15) and Northstrive Fund II LP (5.05%, Schedule 13D, filed 2026-02-20).
Who are the largest shareholders of enVVeno Medical Corp?
By the share each holder's latest filing reports, the largest holders of enVVeno Medical Corp on this page are Thomas A. Satterfield, Jr. (9%), Kingdon Capital Management, L.L.C. (5.5%) and Northstrive Fund II LP (5.05%).
When did Thomas A. Satterfield, Jr. buy into enVVeno Medical Corp?
The filings give report dates, not purchase dates. The earliest filing from Thomas A. Satterfield, Jr. on this page is the Schedule 13G, filed 2025-11-19, reporting 9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for enVVeno Medical Corp. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.